Pacira BioSciences Executive Compensation (FY25)
PCRX · Executive and director compensation, fiscal 2025 only
The paid brief on Pacira BioSciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 11, 2026
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
130 figures on this page: 128 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
More on Pacira BioSciences
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Pacira BioSciences' chief executive and what were they paid?
Frank Lee, Chief Executive Officer and Director, received $11,636,917 in total compensation for fiscal 2025.
What was Pacira BioSciences' say-on-pay result?
The say-on-pay proposal drew 59.9% of votes cast for or against in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in Pacira BioSciences' peer group?
The disclosed peer group names ACADIA Pharmaceuticals, Inc., Alkermes plc, Amicus Therapeutics, Inc., ANI Pharmaceuticals, Inc. and Blueprint Medicines Corporation, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Frank Lee Chief Executive Officer and Director | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Brendan Teehan Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Slonin Chief Medical Officer | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Kristen Williams Chief Administrative Officer and Secretary | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Shawn Cross Chief Financial Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Brendan Teehan | OPTION | — | — | — | — | — | — | ◇ |
| Brendan Teehan | PSU | — | — | — | — | — | — | ◇ |
| Frank Lee | PSU | — | — | — | — | — | — | ◇ |
| Jonathan Slonin | PSU | — | — | — | — | — | — | ◇ |
| Kristen Williams | PSU | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kristen Williams | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/14/2033 | |
| Option | ◇ | — | ◇ | 6/8/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Jonathan Slonin | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 6/14/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/2/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/8/2032 | |
| RSU | ◇ | ◇ | — | — | |
| Shawn Cross | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 11/4/2034 | |
| Frank Lee | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 1/3/2034 | |
| RSU | ◇ | ◇ | — | — | |
| Brendan Teehan | Option | ◇ | — | ◇ | 2/4/2035 |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Laura Brege Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark Kronenfeld | ◇ | ◇ | ◇ | — | — | — | ◇ |
Alethia Young | ◇ | ◇ | ◇ | — | — | — | ◇ |
Abraham Ceesay | ◇ | ◇ | ◇ | — | — | — | ◇ |
Michael Yang | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark Froimson | ◇ | ◇ | ◇ | — | — | — | ◇ |
Marcelo Bigal | ◇ | ◇ | ◇ | — | — | — | ◇ |
Christopher Christie | ◇ | ◇ | ◇ | — | — | — | ◇ |
Paul Hastings | ◇ | — | — | — | — | ◇ | ◇ |
Samit Hirawat, Frank D. Lee, Andreas Wicki and Thomas Wiggans served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACADIA Pharmaceuticals, Inc. ACAD
- Alkermes plc ALKS
- Amicus Therapeutics, Inc. FOLD
- ANI Pharmaceuticals, Inc. ANIP
- Blueprint Medicines Corporation BPMC
- CareDx, Inc. CDNA
- Corcept Therapeutics, Inc. CORT
- Exelixis, Inc. EXEL
- Halozyme Therapeutics, Inc. HALO
- Ionis Pharmaceuticals, Inc. IONS
- Ironwood Pharmaceuticals, Inc. IRWD
- Organogenesis Holdings, Inc. ORGO
- PTC Therapeutics, Inc. PTCT
- Supernus Pharmaceuticals, Inc. SUPN
- Travere Therapeutics, Inc. TVTX
- Ultragenyx Pharmaceutical, Inc. RARE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 9, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 10, 2025 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact Pacira BioSciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Pacira BioSciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Pacira BioSciences recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
130 figures on this page: 128 cited to the filing that reported them, 2 calculated from figures it prints.
128 cited to the filing
2 calculated from the filing
Documents cited
- 0001628280-26-042525
- 0001104659-26-050353DIRECTOR COMPENSATION TABLE · Director Compensation · OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END TABLE · SUMMARY COMPENSATION TABLE
- 0001104659-25-041219Grants of Plan-Based Awards
- 0001396814-25-000089
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Pacira BioSciences executive compensation, FY2025.” https://intel.velarion.ai/comp/PCRX (accessed 2026).
Short form: data: Velarion
The paid brief for Pacira BioSciences
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Pacira BioSciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Pacira BioSciences discloses
The companies named in PCRX's own disclosed peer group.
ACADIA Pharmaceuticals, Inc.Alkermes plcAmicus Therapeutics, Inc.ANI Pharmaceuticals, Inc.Blueprint Medicines CorporationCareDx, Inc.Corcept Therapeutics, Inc.Exelixis, Inc.Halozyme Therapeutics, Inc.Ionis Pharmaceuticals, Inc.Ironwood Pharmaceuticals, Inc.Organogenesis Holdings, Inc.PTC Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Travere Therapeutics, Inc.Ultragenyx Pharmaceutical, Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}